Drug Trial Radar · NCT02781727
A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)
Last checked: Nov 20, 2026Latest source record: Jul 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
162
Actual
Start
Dec 13, 2016
Primary completion
Jan 17, 2019
Study completion Jan 17, 2019
Sponsor
- Lead sponsor
- Ascendis Pharma Endocrinology Division A/SIndustry
- Sponsor type
- Industry
- First posted
- May 24, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 3 years, up to 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A 52 week trial of TransCon hGH, a long-acting growth hormone product, versus human growth hormone therapy. TransCon hGH will be given once-a-week, human growth hormone (hGH) will be given daily. Approximately 150 prepubertal, hGH-treatment naïve children (males and females) with GHD will be included. Randomization will occur in a 2:1 ratio (TransCon hGH : Genotropin). This is a global trial that will be conducted in Armenia, Australia, Belarus, Bulgaria, Georgia, Greece, Italy, New Zealand, Poland, Romania, Russia, Turkey, Ukraine, and the United States.
Conditions
- Growth Hormone Deficiency, Pediatric
- hGH (Human Growth Hormone)
- Endocrine System Diseases
- Hormones
- Pituitary Diseases
Interventions
Once weekly subcutaneous injection of TransCon hGHDrug
Once weekly subcutaneous injection
Once daily subcutaneous injection of GenotropinDrug
Once daily subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Height Velocity at 52 Weeks for Weekly Lonapegsomatropin and Daily hGH Treatment GroupsTime frame: 52 weeks
Locations
53 sites in 14 countries. Site status is shown where the registry gives one.
Ascendis Pharma Investigational Site
Birmingham, Alabama
Ascendis Pharma Investigational Site
Little Rock, Arkansas
Ascendis Pharma Investigational Site
Los Angeles, California
Ascendis Pharma Investigational Site
Orange, California
Ascendis Pharma Investigational Site
Centennial, Colorado
Ascendis Pharma Investigational Site
Jacksonville, Florida
Ascendis Pharma Investigational Site
Orlando, Florida
Ascendis Pharma Investigational Site
Saint Paul, Minnesota
Ascendis Pharma Investigational Site
Jackson, Mississippi
Ascendis Pharma Investigational Site
Lebanon, New Hampshire
Ascendis Pharma Investigational Site
Mineola, New York
Ascendis Pharma Investigational Site
Oklahoma City, Oklahoma
Ascendis Pharma Investigational Site
Portland, Oregon
Ascendis Pharma Investigational Site
Dallas, Texas
Ascendis Pharma Investigational Site
Fort Worth, Texas
Ascendis Pharma Investigational Site
Tacoma, Washington
Ascendis Pharma Investigational Site
Yerevan, Armenia
Ascendis Pharma Investigational Site
Clayton, Australia
Ascendis Pharma Investigational Site
Minsk, Belarus
Ascendis Pharma Investigational Site
Varna, Bulgaria
Ascendis Pharma Investigational Site
Tbilisi, Georgia
Ascendis Pharma Investigational Site
Tbilisi, Georgia
Ascendis Pharma Investigational Site
Tbilisi, Georgia
Ascendis Pharma Investigational Site
Athens, Greece
Ascendis Pharma Investigational Site
Milan, Italy
Ascendis Pharma Investigational Site
Roma, Italy
Ascendis Pharma Investigational Site
Grafton, New Zealand
Ascendis Pharma Investigatonal Site
Gdansk, Poland
Ascendis Pharma Investigational Site
Warsaw, Poland
Ascendis Pharma Investigational Site
Iași, Romania
Ascendis Pharma Investigational Site
Izhevsk, Russia
Ascendis Pharma Investigational Site
Kazan', Russia
Ascendis Pharma Investigational Site
Krasnoyarsk, Russia
Ascendis Pharma Investigational Site
Moscow, Russia
Ascendis Pharma Investigational Site
Moscow, Russia
Ascendis Pharma Investigational Site
Nizhny Novgorod, Russia
Ascendis Pharma Investigational Site
Novosibirsk, Russia
Ascendis Pharma Investigational Site
Omsk, Russia
Ascendis Pharma Investigational Site
Saint Petersburg, Russia
Ascendis Pharma Investigational Site
Saint Petersburg, Russia
Showing 40 of 53 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.